Haleon (HLN) Stock Forecast & Price Target

$10.04 +0.42 (+4.31%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$10.04 -0.01 (-0.06%)

As of 05:10 AM Eastern

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
0

Hold
6

Buy
2

Based on 8 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 6 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for HLN.

Consensus Price Target

$10.95
9.01% Upside

According to the 8 analysts' twelve-month price targets for Haleon, the average price target is $10.95. The highest price target for HLN is $10.95, while the lowest price target for HLN is $10.95. The average price target represents a forecasted upside of 9.01% from the current price of $10.05.

Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

HLN Analyst Ratings Over Time

Type	Current Forecast 4/14/24 to 4/14/25	1 Month Ago 3/15/24 to 3/15/25	3 Months Ago 1/15/24 to 1/14/25	1 Year Ago 4/15/23 to 4/14/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.95	$10.95	$10.95	N/A
Forecasted Upside	9.01% Upside	7.83% Upside	21.40% Upside	N/A
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

Remove Ads

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Haleon Stock vs. The Competition

Type	Haleon	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.82	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	9.01% Upside	21,704.72% Upside	27.84% Upside
News Sentiment Rating	Positive News See Recent HLN News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
3/5/2025	Hsbc Global Res 0 of 5 stars	J. Fialko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/5/2025	HSBC 2 of 5 stars		Reiterated Rating	Buy ➝ Hold
3/3/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Reiterated Rating	Hold ➝ Hold
1/10/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
1/8/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Elliott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Delmas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Davies Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Nicolai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
8/8/2023	Investec Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
5/24/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:31 AM ET.

Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, April 6, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

Here are some ways that investors could benefit from investing in Haleon plc:

Haleon plc reported a revenue of $3.54 billion during the latest quarter, exceeding the consensus estimate of $3.38 billion, indicating strong financial performance and potential for growth.
The company has a return on equity of 14.76%, which suggests effective management in generating profits from shareholders' equity, a positive sign for investors.
Haleon plc recently increased its dividend to $0.1166 per share, up from $0.05, reflecting a commitment to returning value to shareholders. This increase represents a yield of 1.6%, which can be attractive for income-focused investors.
The current stock price of Haleon plc is $10.30, which is near its 52-week high of $10.80, indicating strong market interest and potential for further appreciation.
Institutional investors and hedge funds own 6.67% of Haleon plc's stock, suggesting confidence from large financial entities in the company's future performance.

Haleon
Bear Case

Investors should be bearish about investing in Haleon plc for these reasons:

Despite the positive revenue growth, the company has a relatively high P/E ratio of 30.28, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
Recent analyst ratings show a consensus rating of "Hold," with several brokerages downgrading their ratings, which may suggest a lack of strong bullish sentiment in the market.
The stock has a beta of 0.25, indicating lower volatility compared to the market. While this can be seen as stability, it may also limit potential high returns for aggressive investors.
Haleon plc's net margin of 10.85% is decent but may not be competitive compared to other companies in the consumer healthcare sector, which could affect long-term profitability.
Recent trading volumes have shown fluctuations, with a significant drop in trading activity compared to its average volume, which may indicate reduced investor interest or confidence.

HLN Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $10.95, with a high forecast of $10.95 and a low forecast of $10.95.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There are currently 6 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLN, but not buy additional shares or sell existing shares.
: According to analysts, Haleon's stock has a predicted upside of 9.01% based on their 12-month stock forecasts.
: Over the previous 90 days, Haleon's stock had 1 downgrade by analysts.
: Haleon has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Hsbc Global Res, and HSBC in the past 90 days.
: Analysts like Haleon less than other "medical" companies. The consensus rating for Haleon is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HLN) was last updated on 4/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haleon (HLN) Stock Forecast & Price Target